R A Brodsky

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi High-dose cyclophosphamide for aplastic anemia and autoimmunity
    Robert A Brodsky
    Johns Hopkins Oncology Center, Baltimore, Maryland 21231 1000, USA
    Curr Opin Oncol 14:143-6. 2002
  2. pmc The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells
    Jeffrey J Pu
    Division of Hematology, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
    Haematologica 97:1225-33. 2012
  3. doi High-dose cyclophosphamide for autoimmunity and alloimmunity
    Robert A Brodsky
    The Division of Hematology, Johns Hopkins University School of Medicine, Ross Research Building, Baltimore, MD 21205, USA
    Immunol Res 47:179-84. 2010
  4. ncbi Acquired severe aplastic anemia in children: is there a standard of care?
    Robert Brodsky
    Sidney Kimmel Comprehensive, Cancer Center at Johns Hopkins, Baltimore 21205, MD
    Pediatr Blood Cancer 43:711-2. 2004
  5. ncbi Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
    Robert A Brodsky
    Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
    Blood 111:1840-7. 2008
  6. ncbi Aplastic anaemia
    Robert A Brodsky
    Johns Hopkins University School of Medicine, Division of Hematology, and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Lancet 365:1647-56. 2005
  7. ncbi PIG-A mutations in paroxysmal nocturnal hemoglobinuria and in normal hematopoiesis
    Robert A Brodsky
    Johns Hopkins University School of Medicine, Division of Hematology, Baltimore, MD, USA
    Leuk Lymphoma 47:1215-21. 2006
  8. pmc Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria
    Robert A Brodsky
    The Division of Hematology, Johns Hopkins, University School of Medicine, 720 Rutland Avenue, Ross Research Building, Room 1025, Baltimore, MD 21205, United States
    Blood Rev 22:65-74. 2008
  9. ncbi Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement-related hemolytic anemia
    Robert A Brodsky
    Division of Hematology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205 2196, USA
    Ann Intern Med 148:587-95. 2008
  10. pmc Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases
    R A Brodsky
    Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 2196, USA
    Bone Marrow Transplant 42:523-7. 2008

Detail Information

Publications60

  1. ncbi High-dose cyclophosphamide for aplastic anemia and autoimmunity
    Robert A Brodsky
    Johns Hopkins Oncology Center, Baltimore, Maryland 21231 1000, USA
    Curr Opin Oncol 14:143-6. 2002
    ....
  2. pmc The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells
    Jeffrey J Pu
    Division of Hematology, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
    Haematologica 97:1225-33. 2012
    ..Here, we investigate the origin and clonality of small glycosylphosphatidylinositol-anchor deficient cell populations in aplastic anemia and myelodysplastic syndromes...
  3. doi High-dose cyclophosphamide for autoimmunity and alloimmunity
    Robert A Brodsky
    The Division of Hematology, Johns Hopkins University School of Medicine, Ross Research Building, Baltimore, MD 21205, USA
    Immunol Res 47:179-84. 2010
    ..This article describes the clinical translation of high-CY for the treatment of autoimmune and alloimmune conditions...
  4. ncbi Acquired severe aplastic anemia in children: is there a standard of care?
    Robert Brodsky
    Sidney Kimmel Comprehensive, Cancer Center at Johns Hopkins, Baltimore 21205, MD
    Pediatr Blood Cancer 43:711-2. 2004
  5. ncbi Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
    Robert A Brodsky
    Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
    Blood 111:1840-7. 2008
    ..This trial is registered at http://clinicaltrials.gov as NCT00130000...
  6. ncbi Aplastic anaemia
    Robert A Brodsky
    Johns Hopkins University School of Medicine, Division of Hematology, and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Lancet 365:1647-56. 2005
    ..Acquired aplastic anaemia can be effectively treated by allogeneic bone-marrow transplantation, immunosuppression (generally antithymocyte globulin and ciclosporin), and high-dose cyclophosphamide...
  7. ncbi PIG-A mutations in paroxysmal nocturnal hemoglobinuria and in normal hematopoiesis
    Robert A Brodsky
    Johns Hopkins University School of Medicine, Division of Hematology, Baltimore, MD, USA
    Leuk Lymphoma 47:1215-21. 2006
    ..This review examines the clinical and biological relevance of PIG-A mutations in PNH, aplastic anemia and healthy controls...
  8. pmc Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria
    Robert A Brodsky
    The Division of Hematology, Johns Hopkins, University School of Medicine, 720 Rutland Avenue, Ross Research Building, Room 1025, Baltimore, MD 21205, United States
    Blood Rev 22:65-74. 2008
    ..The recently FDA approved complement inhibitor eculizumab has been shown to decrease hemolysis, decrease erythrocyte transfusion requirements, decrease the risk for thrombosis and improve quality of life for PNH patients...
  9. ncbi Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement-related hemolytic anemia
    Robert A Brodsky
    Division of Hematology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205 2196, USA
    Ann Intern Med 148:587-95. 2008
  10. pmc Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases
    R A Brodsky
    Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 2196, USA
    Bone Marrow Transplant 42:523-7. 2008
    ..Nonmyeloablative, HLA-haploidentical BMT with post-transplant CY is a promising approach for patients with life-threatening nonmalignant hematologic disease who lack an HLA-matched sibling donor...
  11. pmc How I treat paroxysmal nocturnal hemoglobinuria
    Robert A Brodsky
    Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205 2196, USA
    Blood 113:6522-7. 2009
    ..Insights into the relevance of detecting PNH cells in PNH and other bone marrow failure disorders are highlighted, and indications for treating PNH patients with bone marrow transplantation and eculizumab are explored...
  12. pmc High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up
    Robert A Brodsky
    Division of Hematology, Department of Medicine, Johns Hopkins University School ofMedicine, 720 Rutland Ave, Ross Bldg, Rm 1025, Baltimore, MD 21205, USA
    Blood 115:2136-41. 2010
    ....
  13. ncbi Riddle: what do aplastic anemia, acute promyelocytic leukemia, and chronic myeloid leukemia have in common?
    R A Brodsky
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Leukemia 18:1740-2. 2004
    ....
  14. pmc Intensive immunosuppression with high dose cyclophosphamide but without stem cell rescue for severe autoimmunity: advantages and disadvantages
    Robert A Brodsky
    The Division of Hematology, Johns Hopkins University School of Medicine, Ross Research Building, Baltimore, MD 21205, USA
    Autoimmunity 41:596-600. 2008
    ....
  15. pmc Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma
    Y L Kasamon
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Ann Oncol 21:1203-10. 2010
    ..Rituximab may improve transplant outcomes but may delay immunologic recovery...
  16. pmc HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 14:641-50. 2008
    ..02). Nonmyeloablative HLA-haploidentical BMT with posttransplantation Cy is associated with acceptable rates of fatal graft failure and severe aGVHD or cGVHD...
  17. pmc Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen
    J Bolanos-Meade
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Bone Marrow Transplant 43:477-80. 2009
    ..The combination of fludarabine and alemtuzumab is an effective and well-tolerated salvage conditioning regimen for patients who experience graft failure after blood or marrow transplants...
  18. ncbi Hematopoietic stem cell transplantation for systemic lupus erythematosus
    R A Brodsky
    Division of Immunology and Hematopoiesis, Johns Hopkins Oncology Center, Baltimore, Maryland, USA
    Rheum Dis Clin North Am 26:377-87, viii. 2000
    ..Early results employing immunoablative therapy, with or without stem cell rescue, are encouraging; however, longer follow-up and additional patients are necessary to validate this approach...
  19. ncbi Long-term results of blood and marrow transplantation for Hodgkin's lymphoma
    G Akpek
    Johns Hopkins Oncology Center, Baltimore, MD 21231, USA
    J Clin Oncol 19:4314-21. 2001
    ..CONCLUSION: There seems to be a clinical graft-versus-HL effect associated with allo BMT. Allo BMT for HL also seems to have a lower risk of secondary AML/MDS than auto BMT. Thus, allo BMT warrants continued study in HL...
  20. ncbi Multilineage glycosylphosphatidylinositol anchor-deficient haematopoiesis in untreated aplastic anaemia
    G L Mukhina
    Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA
    Br J Haematol 115:476-82. 2001
    ..These studies demonstrate that aerolysin-based assays can reveal previously undetectable multilineage PNH cells in patients with untreated aplastic anaemia. Thus, clonality appears to be an early feature of aplastic anaemia...
  21. ncbi High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus
    Michelle Petri
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Arthritis Rheum 48:166-73. 2003
    ..We undertook this study to investigate the safety and efficacy of high-dose cyclophosphamide without stem cell transplantation in refractory SLE...
  22. ncbi Elimination of alloantibodies by immunoablative high-dose cyclophosphamide
    R A Brodsky
    Johns Hopkins Oncology Center, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Transplantation 71:482-4. 2001
    ..We now examine the ability of high-dose cyclophosphamide to eliminate alloreactivity...
  23. ncbi Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia
    R A Brodsky
    Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, Room 242, 1650 Orleans Street, Baltimore MD 21231, USA
    Ann Intern Med 135:477-83. 2001
    ..A small pilot study demonstrated that high-dose cyclophosphamide therapy without bone marrow transplantation leads to durable, treatment-free complete remission...
  24. doi Successful liver transplantation for Budd-Chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria treated with the anti-complement antibody eculizumab
    Andrew L Singer
    Department of Surgery, Comprehensive Transplant Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Liver Transpl 15:540-3. 2009
    ..Here we present the first report of a patient with PNH and BCS undergoing successful liver transplantation while receiving eculizumab, a humanized monoclonal antibody that blocks the activation of the terminal complement at C5...
  25. ncbi Treatment of hepatitis-associated aplastic anemia with high-dose cyclophosphamide
    William J Savage
    Department of Pediatric Oncology, Johns Hopkins Hospital, Baltimore, Maryland, USA
    Pediatr Blood Cancer 49:947-51. 2007
    ..Demonstrate that high-dose cyclophosphamide (CY) is effective therapy for hepatitis-associated aplastic anemia (HAA)...
  26. ncbi New insights into paroxysmal nocturnal hemoglobinuria
    William J Savage
    The Division of Pediatric Hematology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Hematology 12:371-6. 2007
    ..The recently FDA approved complement inhibitor eculizumab has been shown to decrease hemolysis, decrease erythrocyte transfusion requirements, and improve quality of life for PNH patients...
  27. pmc PIG-A mutations in normal hematopoiesis
    Rong Hu
    Johns Hopkins University, School of Medicine, Division of Hematology, Baltimore, MD 21205, USA
    Blood 105:3848-54. 2005
    ..Our data confirm the finding that PIG-A mutations are relatively common in normal hematopoiesis; however, the finding suggests that these mutations occur in differentiated progenitors rather than HSCs...
  28. ncbi Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 12:414-21. 2006
    ..However, with the exception of CML, most patients die of their underlying disease because of insufficient antitumor activity even with active GVHD...
  29. doi Cyclophosphamide and cancer: golden anniversary
    Ashkan Emadi
    Division of Adult Hematology, Johns Hopkins University, Baltimore, MD, USA
    Nat Rev Clin Oncol 6:638-47. 2009
    ..We also discuss the development of high-dose cyclophosphamide for BMT and the treatment of autoimmune diseases...
  30. ncbi High dose cyclophosphamide treatment for autoimmune disorders
    Robert A Brodsky
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Division of Hematologic Malignancies, Baltimore, MD 21231 1000, USA
    ScientificWorldJournal 2:1808-15. 2002
    ..Intensive investigation is underway to determine which autoimmune disorders will most benefit and where in the natural history of these diseases to employ this rapidly developing therapy...
  31. pmc High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial
    Michelle Petri
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Arthritis Rheum 62:1487-93. 2010
    ..We undertook this study to compare the efficacy and safety of the standard regimen versus a high-dose IV cyclophosphamide regimen...
  32. ncbi Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells
    Carol Ann Huff
    Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Baltimore, MD, USA
    Biol Blood Marrow Transplant 9:312-9. 2003
    ..Unlike chronic myelogenous leukemia, the antimyeloma effect of allogeneic T cells rarely occurs in the absence of clinically significant GVHD...
  33. pmc Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome
    Yvette L Kasamon
    Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 16:482-9. 2010
    ..55, P = .03 for 3-4 vs fewer allele mismatches). Thus, greater HLA disparity does not appear to worsen overall outcome after NMA haploidentical BMT with high-dose posttransplantation cyclophosphamide...
  34. ncbi Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience
    B Douglas Smith
    Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, Rm 246, 1650 Orleans Street, Baltimore, MD 21231, USA
    Br J Haematol 117:907-13. 2002
    ..4HC-purged autologous BMT produced results similar to allogeneic BMT for AML patients beyond first remission...
  35. ncbi High-dose cyclophosphamide as salvage therapy for severe aplastic anemia
    Robert A Brodsky
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Exp Hematol 32:435-40. 2004
    ..The aim of this study was to evaluate high-dose cyclophosphamide in patients with refractory severe aplastic anemia (SAA)...
  36. pmc Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF
    B Douglas Smith
    Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
    Leuk Res 35:87-94. 2011
    ..We developed a dose finding trial to assess toxicity, differentiating activity, and clinical impact of the combination of bryostatin-1 and GM-CSF...
  37. ncbi Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes
    W H Matsui
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Leukemia 20:458-62. 2006
    ..Quantification of marrow CD34+ cells may serve as an important tool for distinguishing between AA and hMDS...
  38. pmc Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH
    William J Savage
    Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 2196, USA
    Exp Hematol 37:42-51. 2009
    ..Investigate the contribution of PIG-A mutations to clonal expansion in paroxysmal nocturnal hemoglobinuria (PNH)...
  39. ncbi Enhanced cytotoxicity of rituximab following genetic and biochemical disruption of glycosylphosphatidylinositol anchored proteins
    Nagaprasad Nagajothi
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Leuk Lymphoma 45:795-9. 2004
    ..Thus, genetic and biochemical interruption of GPI anchor proteins augments sensitivity to rituximab...
  40. doi Blood and marrow transplantation for sickle cell disease: overcoming barriers to success
    Javier BolaƱos-Meade
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Curr Opin Oncol 21:158-61. 2009
    ..The objective of this report is to review the most recent clinical trials involving blood and BMT for SCD and to discuss novel approaches to overcome the many barriers to successful use of BMT for SCD...
  41. ncbi The role of growth factors in the activity of pharmacological differentiation agents
    William H Matsui
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Cell Growth Differ 13:275-83. 2002
    ..These data suggest that many pharmacological differentiating agents require both cell cycle arrest and lineage-specific growth factors for full activity and may explain why these agents have demonstrated only limited clinical efficacy...
  42. ncbi Bone marrow transplantation in Shwachman-Diamond syndrome
    J W Hsu
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Bone Marrow Transplant 30:255-8. 2002
    ..Although experience is limited, a review of the reported cases suggests patients with SDS may be transplanted without significant short-term morbidity and mortality...
  43. ncbi High-dose cyclophosphamide without stem cell rescue in scleroderma
    C V Tehlirian
    Department of Medicine, Johns Hopkins Medical Institution, Baltimore, Maryland, USA
    Ann Rheum Dis 67:775-81. 2008
    ..To investigate the safety and tolerability of high-dose cyclophosphamide without stem cell rescue in scleroderma...
  44. ncbi Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays
    Victor M Moyo
    Department of Medicine, Division of Hematology Oncology, University of Connecticut Health Center, Farmington, CT, USA
    Br J Haematol 126:133-8. 2004
    ..These data not only confirm that the size of the PNH clone correlates with the risk for thrombosis, but they also suggest a correlation of PNH clone size to more symptomatic PNH...
  45. pmc Trophoblast differentiation defect in human embryonic stem cells lacking PIG-A and GPI-anchored cell-surface proteins
    Guibin Chen
    Stem Cell Program, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Cell Stem Cell 2:345-55. 2008
    ..These data reveal that GPI-AP-enhanced full activation of BMP signaling is required for human trophoblast formation...
  46. ncbi High-dose therapy for autoimmune neurologic diseases
    Daniel B Drachman
    Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland 21287 7519, USA
    Curr Opin Oncol 17:83-8. 2005
    ..This paper reviews the rationale, methods, and recent results of high-dose therapy and the questions that it raises...
  47. ncbi High-dose cyclophosphamide for refractory autoimmune hemolytic anemia
    Victor M Moyo
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Blood 100:704-6. 2002
    ..High-dose cyclophosphamide was well tolerated and induced durable remissions in patients with severe refractory autoimmune hemolytic anemia...
  48. ncbi Severe aplastic anemia associated with paroxysmal nocturnal hemoglobinuria and lymphoplasmacytic lymphoma
    Robin G Veidt
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland 21205, USA
    Leuk Lymphoma 46:1243-6. 2005
    ..An insult to the hematological stem cell compartment may result in multiple pathological entities, potentially influencing our approach to the treatment of hematological clonal disorders...
  49. ncbi Catheter-directed thrombolysis and thrombectomy for the Budd-Chiari syndrome in paroxysmal nocturnal hemoglobinuria in three patients
    George P Kuo
    Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD 21287 4010, USA
    J Vasc Interv Radiol 17:383-7. 2006
    ..This treatment represents a potential bridge toward more curative therapies such as allogeneic bone marrow transplant...
  50. ncbi A rapid spectrophotometric screening assay for paroxysmal nocturnal hemoglobinuria
    Galina L Mukhina
    Department of Oncology, Johns Hopkins University, Baltimore, MD, USA
    Acta Haematol 107:182-4. 2002
  51. ncbi Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide
    Daniel B Drachman
    Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
    Ann Neurol 53:29-34. 2003
    ..High-dose cyclophosphamide treatment appears to be an effective and safe treatment for selected patients with refractory MG. Further follow-up of these and additional patients will be needed to determine whether the benefit is durable...
  52. pmc Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis
    Chitra Krishnan
    Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287 5371, USA
    Arch Neurol 65:1044-51. 2008
    ..To explore the safety and effectiveness of high-dose cyclophosphamide (HiCy) without bone marrow transplantation in patients with aggressive multiple sclerosis (MS)...
  53. pmc Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis
    Daniel B Drachman
    Department of Neurology, Johns Hopkins School of Medicine, Meyer Building 5 119, 600 North Wolfe Street, Baltimore, MD 21287 7519, USA
    Ann N Y Acad Sci 1132:305-14. 2008
    ..We therefore recommend that treatment of refractory MG with Hi Cy be followed with maintenance immunotherapy...
  54. pmc Silencing of genes required for glycosylphosphatidylinositol anchor biosynthesis in Burkitt lymphoma
    Rong Hu
    Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 2196, USA
    Exp Hematol 37:423-434.e2. 2009
    ..To investigate the mechanism of glycosylphosphatidylinositol (GPI) anchor deficiency in Burkitt lymphoma cell lines...
  55. ncbi The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
    Peter Hillmen
    Leeds General Infirmary, Leeds, United Kingdom
    N Engl J Med 355:1233-43. 2006
    ..We tested the safety and efficacy of eculizumab, a humanized monoclonal antibody against terminal complement protein C5 that inhibits terminal complement activation, in patients with paroxysmal nocturnal hemoglobinuria (PNH)...
  56. ncbi Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
    Peter Hillmen
    Leeds General Infirmary, Leeds, United Kingdom
    Blood 110:4123-8. 2007
    ..001). These results show that eculizumab treatment reduces the risk of clinical thromboembolism in patients with PNH. This study is registered at http://clinicaltrials.gov (study ID no. NCT00122317)...
  57. ncbi High-dose cyclophosphamide in severe aplastic anaemia
    Richard J Jones
    Br J Haematol 125:408-9; author reply 409-10. 2004
  58. ncbi Parvovirus b19-associated pure red cell aplasia in chronic graft-versus-host disease
    Jack W Hsu
    Br J Haematol 119:280-1. 2002
  59. ncbi Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
    Russell P Rother
    Alexion Pharmaceuticals, Inc, 352 Knotter Drive, Cheshire, Connecticut 06410, USA
    Nat Biotechnol 25:1256-64. 2007
    ....
  60. ncbi Paroxysmal nocturnal hemoglobinuria arising from Fanconi anemia
    Linda Wainwright
    University of the Witwatersrand, Chris Hani Baragwanath Hospital, Johannesburg, South Africa
    J Pediatr Hematol Oncol 25:167-8. 2003
    ..Modern diagnostic methods are used to confirm this process. A discussion of possible mechanisms ensues...